表紙
市場調查報告書

全球子宮頸癌症治療藥市場:2020年∼2024年的預測

Global Cervical Cancer Therapeutics Market 2020-2024

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 843043
出版日期 內容資訊 英文 120 Pages
訂單完成後即時交付
價格
全球子宮頸癌症治療藥市場:2020年∼2024年的預測 Global Cervical Cancer Therapeutics Market 2020-2024
出版日期: 2020年03月06日內容資訊: 英文 120 Pages
簡介

全球子宮頸癌症治療藥市場在預測期間內,預計將以7%的年複合成長率增長,2024年達到10億6,000萬美元。市場成長的主要因素有子宮頸癌症的盛行率增加。再加上T細胞免疫療法的開發,有望在預測期內促進市場增長。

本報告提供全球子宮頸癌症治療藥市場的相關調查,提供市場趨勢和課題,成長要素,各類型·各地區的市場分析,業者情勢,主要企業的簡介等資訊。

目錄

摘要整理

市場預測

市場規模

  • 市場定義
  • 市場區隔分析
  • 市場規模:2019年
  • 市場預測:2019-2024年的預測

波特的五力分析

市場區隔:各類型

  • 市場區隔
  • 比較
  • 醫藥品
  • 疫苗
  • 市場機會

客戶形勢

  • 概要

地區形勢

  • 市場區隔
  • 比較
  • 北美
  • 歐洲
  • 亞洲
  • 其他地區
  • 主要國家
  • 市場機會

市場成長要素,課題,及趨勢

  • 市場成長要素
  • 交易量的成長要素:需求主導的成長
  • 交易量的成長要素:供給主導的成長
  • 交易量的成長要素:外部要素
  • 交易量的成長要素-需求轉移到鄰近市場
  • 價格成長要素:通貨膨脹
  • 價格成長要素-從低價格單位轉變到高價格單位
  • 市場課題
  • 市場趨勢

業者情勢

  • 概要
  • 形勢的創新

企業簡介

  • 交易廠商
  • 供應商的市場上地位
  • Amgen Inc.
  • Biocon Ltd.
  • Cipla Inc.
  • Dr. Reddy's Laboratories Ltd.
  • F. Hoffmann-La Roche Ltd.
  • Fresenius SE & Co. KGaA
  • GlaxoSmithKline Plc
  • Merck & Co. Inc.
  • Novartis AG
  • Pfizer Inc.

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: IRTNTR41609

Technavio has been monitoring the global cervical cancer therapeutics market 2020-2024 and it is poised to grow by USD 1.06 bn during 2020-2024, progressing at a CAGR of 7% during the forecast period. Our reports on global cervical cancer therapeutics market 2020-2024 provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by increasing prevalence of cervical cancer. In addition, the development of t-cell immunotherapy is anticipated to boost the growth of the global cervical cancer therapeutics market 2020-2024 as well.

Market Segmentation

Technavio's ‘ global cervical cancer therapeutics market 2020-2024’ is segmented as below:

Type:

  • Drugs
  • Vaccines

Geographic segmentation

  • Asia
  • Europe
  • North America
  • ROW

Key Trends for global cervical cancer therapeutics market 2020-2024 growth

This study identifies the development of t-cell immunotherapy as the prime reasons driving the global cervical cancer therapeutics market 2020-2024 growth during the next few years.

Prominent vendors in global cervical cancer therapeutics market 2020-2024

We provide a detailed analysis of around 25 vendors operating in the global cervical cancer therapeutics market 2020-2024, including some of the vendors such as Amgen Inc., Biocon Ltd., Cipla Inc., Dr. Reddy's Laboratories Ltd., F. Hoffmann-La Roche Ltd., Fresenius SE & Co. KGaA, GlaxoSmithKline Plc, Merck & Co. Inc., Novartis AG and Pfizer Inc. .

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. Technavio's market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast an accurate market growth.

Table of Contents

Executive Summary

  • Market Overview

Market Landscape

  • Market ecosystem
  • Value chain analysis

Market Sizing

  • Market definition
  • Market segment analysis
  • Market size 2019
  • Market outlook: Forecast for 2019 - 2024

Five Forces Analysis

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

Market Segmentation by Type

  • Market segments
  • Comparison by Type placement
  • Drugs - Market size and forecast 2019-2024
  • Vaccines - Market size and forecast 2019-2024
  • Market opportunity by Type

Customer landscape

  • Overview

Geographic Landscape

  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2019-2024
  • Europe - Market size and forecast 2019-2024
  • Asia - Market size and forecast 2019-2024
  • ROW - Market size and forecast 2019-2024
  • Key leading countries
  • Market opportunity by geography

Drivers, Challenges, and Trends

  • Market drivers
  • Volume driver - Demand led growth
  • Volume driver - Supply led growth
  • Volume driver - External factors
  • Volume driver - Demand shift in adjacent markets
  • Price driver - Inflation
  • Price driver - Shift from lower to higher-priced units
  • Market challenges
  • Market trends

Vendor Landscape

  • Overview
  • Landscape disruption

Vendor Analysis

  • Vendors covered
  • Market positioning of vendors
  • Amgen Inc.
  • Biocon Ltd.
  • Cipla Inc.
  • Dr. Reddy's Laboratories Ltd.
  • F. Hoffmann-La Roche Ltd.
  • Fresenius SE & Co. KGaA
  • GlaxoSmithKline Plc
  • Merck & Co. Inc.
  • Novartis AG
  • Pfizer Inc.

Appendix

  • Scope of the report
  • Currency conversion rates for US$
  • Research methodology
  • List of abbreviations

List of Exhibits:

  • 1.Key Finding 1
  • 2.Key Finding 2
  • 3.Key Finding 3
  • 4.Key Finding 5
  • 5.Key Finding 6
  • 6.Key Finding 7
  • 7.Key Finding 8
  • 8.Market in focus
  • 9.Parent market
  • 10.Market characteristics
  • 11.Product / Service portfolio of key vendors included in the market definition
  • 12.Market segments
  • 13.
  • 14.Global - Market size and forecast 2019 - 2024 ($ million)
  • 15.Global market: Year-over-year growth 2019 - 2024 (%)
  • 16.Five forces analysis 2019 & 2024
  • 17.Bargaining power of buyers
  • 18.Bargaining power of suppliers
  • 19.Threat of new entrants
  • 20.Threat of substitutes
  • 21.Threat of rivalry
  • 22.Market condition - Five forces 2019
  • 23.Type placement - Market share 2019-2024 (%)
  • 24.Comparison by Type placement
  • 25.Drugs - Market size and forecast 2019-2024 ($ million)
  • 26.Drugs - Year-over-year growth 2019-2024 (%)
  • 27.Vaccines - Market size and forecast 2019-2024 ($ million)
  • 28.Vaccines - Year-over-year growth 2019-2024 (%)
  • 29. Market opportunity by Type
  • 30.Customer landscape
  • 31.Market share by geography 2019-2024 (%)
  • 32.Geographic comparison
  • 33.North America - Market size and forecast 2019-2024 ($ million)
  • 34.North America - Year-over-year growth 2019-2024 (%)
  • 35.Europe - Market size and forecast 2019-2024 ($ million)
  • 36.Europe - Year-over-year growth 2019-2024 (%)
  • 37.Asia - Market size and forecast 2019-2024 ($ million)
  • 38.Asia - Year-over-year growth 2019-2024 (%)
  • 39.ROW - Market size and forecast 2019-2024 ($ million)
  • 40.ROW - Year-over-year growth 2019-2024 (%)
  • 41.Key leading countries
  • 42.Market opportunity by geography ($ million)
  • 43.Impact of drivers and challenges
  • 44.Vendor landscape
  • 45.Landscape disruption
  • 46.Industry risks
  • 47.Vendors covered
  • 48.Market positioning of vendors
  • 49.Amgen Inc. - Overview
  • 50.Amgen Inc. - Business segments
  • 51.Amgen Inc. - Key offerings
  • 52.Amgen Inc. - Key customers
  • 53.Amgen Inc. - Segment focus
  • 54.Biocon Ltd. - Overview
  • 55.Biocon Ltd. - Business segments
  • 56.Biocon Ltd. - Key offerings
  • 57.Biocon Ltd. - Key customers
  • 58.Biocon Ltd. - Segment focus
  • 59.Cipla Inc. - Overview
  • 60.Cipla Inc. - Business segments
  • 61.Cipla Inc. - Key offerings
  • 62.Cipla Inc. - Key customers
  • 63.Cipla Inc. - Segment focus
  • 64.Dr. Reddy's Laboratories Ltd. - Overview
  • 65.Dr. Reddy's Laboratories Ltd. - Business segments
  • 66.Dr. Reddy's Laboratories Ltd. - Key offerings
  • 67.Dr. Reddy's Laboratories Ltd. - Key customers
  • 68.Dr. Reddy's Laboratories Ltd. - Segment focus
  • 69.F. Hoffmann-La Roche Ltd. - Overview
  • 70.F. Hoffmann-La Roche Ltd. - Business segments
  • 71.F. Hoffmann-La Roche Ltd. - Key offerings
  • 72.F. Hoffmann-La Roche Ltd. - Key customers
  • 73.F. Hoffmann-La Roche Ltd. - Segment focus
  • 74.Fresenius SE & Co. KGaA - Overview
  • 75.Fresenius SE & Co. KGaA - Business segments
  • 76.Fresenius SE & Co. KGaA - Key offerings
  • 77.Fresenius SE & Co. KGaA - Key customers
  • 78.Fresenius SE & Co. KGaA - Segment focus
  • 79.GlaxoSmithKline Plc - Overview
  • 80.GlaxoSmithKline Plc - Business segments
  • 81.GlaxoSmithKline Plc - Key offerings
  • 82.GlaxoSmithKline Plc - Key customers
  • 83.GlaxoSmithKline Plc - Segment focus
  • 84.Merck & Co. Inc. - Overview
  • 85.Merck & Co. Inc. - Product and service
  • 86.Merck & Co. Inc. - Key offerings
  • 87.Merck & Co. Inc. - Key customers
  • 88.Merck & Co. Inc. - Segment focus
  • 89.Novartis AG - Overview
  • 90.Novartis AG - Business segments
  • 91.Novartis AG - Key offerings
  • 92.Novartis AG - Key customers
  • 93.Novartis AG - Segment focus
  • 94.Pfizer Inc. - Overview
  • 95.Pfizer Inc. - Business segments
  • 96.Pfizer Inc. - Key offerings
  • 97.Pfizer Inc. - Key customers
  • 98.Pfizer Inc. - Segment focus
  • 99.Currency conversion rates for US$
  • 100.Research Methodology
  • 101.Validation techniques employed for market sizing
  • 102.Information sources
  • 103.List of abbreviations